|
Sanarus Technologies is a medical device company that develops and markets minimally-invasive, office-based breast care diagnosis and treatment solutions to patients and physicians. The company provides cryoablation technology that is used to freeze tissue for diagnostic and therapeutic breast care procedures.〔(Sanarus Medical, Inc. Appoints... )〕 In July 2009, the company purchased the assets of Sanarus Medical, Inc.〔(Sanarus Medical, Inc. Acquired by Investor Group )〕 The company was originally founded in 1999 and is headquartered in Pleasanton, California. == Product Offerings == *Visica 2 Treatment System uses cryoablation to treat biopsy proven fibroadenomas and is currently in a Phase 2 clinical trial for the treatment of breast cancer.〔(Cryoablation of Early Invasive Ductal Breast Cancer )〕 * *In 2008, the Visica 2 Treatment System was named a runner-up in the Medical Device category at the Wall Street Journal's Technology Innovation Awards.〔(Technology Innovation Awards 2008 )〕 * *In 2008, the American College of Surgeons Oncology Group chose the Visica 2TM Treatment System as the exclusive ablation treatment technology for a National Cancer Institute funded study to explore the success of cryoablation therapy in the treatment of Invasive Breast Carcinoma.〔 *Cassi II Rotational Core Biopsy System is a hand-held and self-contained breast biopsy device that utilizes cryotechnology. *ImarC Tissue Marker System is a breast tissue marking system that is capable of long-term visibility under X-ray, Ultrasound and MRI. 抄文引用元・出典: フリー百科事典『 ウィキペディア（Wikipedia）』 ■ウィキペディアで「Sanarus Technologies」の詳細全文を読む スポンサード リンク
|